Similar articles

• A review of the clinical pharmacology of maraviroc. Introduction.

  Boffito M, Abel S. Boffito M, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):1-4. doi: 10.1111/j.1365-2125.2008.03131.x. Br J Clin Pharmacol. 2008. PMID: 18333860 Free PMC article. No abstract available.
• Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

  Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. Cooper DA, et al. J Infect Dis. 2010 Mar 15;201(6):803-13. doi: 10.1086/650697. J Infect Dis. 2010. PMID: 20151839 Clinical Trial.
• Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients.

  Gonzalez-Serna A, Genebat M, Ruiz-Mateos E, Leal M. Gonzalez-Serna A, et al. Drug Des Devel Ther. 2016 Jan 18;10:353-4. doi: 10.2147/DDDT.S100639. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26848259 Free PMC article. No abstract available.
• Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.

  Lieberman-Blum SS, Fung HB, Bandres JC. Lieberman-Blum SS, et al. Clin Ther. 2008 Jul;30(7):1228-50. doi: 10.1016/s0149-2918(08)80048-3. Clin Ther. 2008. PMID: 18691983 Review.
• [Pharmacological profile and clinical findings of Maraviroc (Celsentri® Tablets)].

  Hizue M. Hizue M. Nihon Yakurigaku Zasshi. 2010 Dec;136(6):349-58. doi: 10.1254/fpj.136.349. Nihon Yakurigaku Zasshi. 2010. PMID: 21139287 Review. Japanese. No abstract available.